Roth_2022_J.Nucl.Med_63_1683

Imaging studies with PET tracers acting as fibroblast activation protein inhibitors (FAPIs) show promising results that could usefully complement [(18)F]-FDG in cancer imaging. Methods: All patients received [(18)F]-FDG PET/CT and dual-tracer PET/CT after an additional injection of [(68)Ga]Ga-FAPI-46 after the [(18)F]-FDG PET/CT. Two readers visually compared detection rate and analyzed target-to-background ratios for tumor and metastatic tissue in single- and dual-tracer PET/CT. Results: Detection rate in dual-tracer PET/CT was visually as good as that in single-tracer PET/CT in 4 patients and superior in 2 patients, whereas target-to-background ratios were significantly higher in dual-tracer PET/CT. Conclusion: Dual-tracer [(18)F]-FDG/[(68)Ga]Ga-FAPI-46 PET/CT within a single session is feasible and has potential. The dual-tracer approach may have superior sensitivity to [(18)F]-FDG PET/CT alone without compromising individual assessment of either scan.